These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24961679)

  • 1. Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience.
    Flemming JA; Vagefi PA; Freise CE; Yao FY; Terrault NA
    Liver Transpl; 2014 Oct; 20(10):1202-10. PubMed ID: 24961679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of liver transplantation waiting list for decompensated cirrhosis in a Spanish tertiary hospital: differences between hepatitis C virus recipients and other etiologies.
    Ibáñez Samaniego L; Pérez Valderas M; Fernández Yunquera A; Rincón Rodríguez D; López Baena JA; Matilla Peña A; Catalina Rodríguez MV; Clemente Ricote G; Bañares Cañizares R; Salcedo Plaza M
    Transplant Proc; 2014 Nov; 46(9):3084-6. PubMed ID: 25420829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics.
    Hung K; Gralla J; Dodge JL; Bambha KM; Dirchwolf M; Rosen HR; Biggins SW
    Liver Transpl; 2015 Nov; 21(11):1365-73. PubMed ID: 25865434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
    Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
    Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
    Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
    Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Flemming JA; Kim WR; Brosgart CL; Terrault NA
    Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
    Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
    J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study.
    Terrault NA; Stravitz RT; Lok AS; Everson GT; Brown RS; Kulik LM; Olthoff KM; Saab S; Adeyi O; Argo CK; Everhart JE; Rodrigo del R;
    Hepatology; 2014 Apr; 59(4):1311-9. PubMed ID: 24677192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Old donors in liver transplantation for chronic hepatitis C].
    Aguilera V; Ponce M; Berenguer M; Moreno R; Rayón JM; Sanjuán F; Prieto M; Mir J
    Rev Esp Enferm Dig; 2007 Oct; 99(10):581-7. PubMed ID: 18052661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection.
    Terrault NA; Roland ME; Schiano T; Dove L; Wong MT; Poordad F; Ragni MV; Barin B; Simon D; Olthoff KM; Johnson L; Stosor V; Jayaweera D; Fung J; Sherman KE; Subramanian A; Millis JM; Slakey D; Berg CL; Carlson L; Ferrell L; Stablein DM; Odim J; Fox L; Stock PG;
    Liver Transpl; 2012 Jun; 18(6):716-26. PubMed ID: 22328294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of live donor liver transplantation in patients with hepatitic C virus infection: the HCV 3 trial experience.
    Sher L; Jennings L; Rudich S; Alexopoulos SP; Netto G; Teperman L; Kinkhabwala M; Brown RS; Pomfret E; Klintmalm G;
    Clin Transplant; 2012; 26(3):502-9. PubMed ID: 22151078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The corrected donor age for hepatitis C virus-infected liver transplant recipients.
    Dirchwolf M; Dodge JL; Gralla J; Bambha KM; Nydam T; Hung KW; Rosen HR; Feng S; Terrault NA; Biggins SW
    Liver Transpl; 2015 Aug; 21(8):1022-30. PubMed ID: 26074140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: a Scandinavian single-center experience.
    Ydreborg M; Westin J; Lagging M; Castedal M; Friman S
    Scand J Gastroenterol; 2012 Jun; 47(6):710-7. PubMed ID: 22452366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
    Tanaka T; Voigt MD
    J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation After Circulatory Death Liver Transplant Grafts Compared With Those Receiving Donation After Brainstem Death Grafts.
    Townsend SA; Monga MA; Nightingale P; Mutimer D; Elsharkawy AM; Holt A
    Transplant Proc; 2017 Nov; 49(9):2129-2134. PubMed ID: 29149973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C.
    Pang PS; Kamal A; Glenn JS
    Liver Transpl; 2009 Sep; 15(9):1126-32. PubMed ID: 19718638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.